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Sumnlary 
The production of cytokines in monocytes/macrophages is regulated by several  different cytokines 
that have activating or inhibitory effects. Interleukin (IL)-10, IL-4, IL-13, and transforming growth 
factor (TGF)-~ are usually considered to be the most important macrophage-deactivating factors, 
with inhibitory effects on cytokine production. Unlike IL-IO and TGF-/3, which appear to act 
as downmodulators of many phagocytic cell functions,  the mode of action of IL-4 and IL-13 
is more complex. Addition of IL-4 and IL-13 to peripheral blood mononuclear cell (PBMC) cul- 
tures inhibited production of II.-12, tumor necrosis factor (TNF)-o~, IL-10, and II:1/~ induced 
by lipopolysaccharide (LPS) or Staphylococcus  aureus  added simultaneously with the cytokines. 
However, pretreatment of PBMC with II.-4 or I1.-13 for >--20 h enhanced the production of I1.-12 
and TNF<~ in response to LPS or S. aureus several fold in these cells; this IL-4-induced priming 
for the two cytokines was inhibited by anti-IL-4 neutralizing antibodies. IL-4 priming also en- 
hanced the accumulation  of IL-12 and TNF-ot  mR.NA induced by LPS and S. aureus.  The en- 
hanced accumulation of transcripts for the 1I.-12 p35 and p40 chains by IL-4 priming was reflected 
in enhanced secretion of both the IL-12 free p40 chain and the p70 heterodimer.  These results 
suggest an unexpected complexity in the regulatory role of IL-4 and IL-13 in immune responses. 
er ability  of monocytes/macrophages to act as APCs 
T cells and as accessory cells for activation of NK 
cells is mediated in part by the expression of costimulatory 
molecules, either present at the cell surface (e.g., B7 and cell 
adhesion molecules) or secreted (e.g., I1.-12, TNF-oz, and IL- 
l). IL-12 is a heterodimeric cytokine produced by several cell 
types with APC function. IL-12 induces production of IFN-'y 
from T and NK cells, proliferation  of activated T and NK 
cells, and enhancement of the cytotoxic activity of lympho- 
cytes (1). Upon infection with bacteria or intracellular para- 
sites,  monocytes/macrophages produce  IL-12 (2),  which 
cooperates with TNF-cx and IL-1 as well as with B7 stimula- 
tion of the CD28 receptor on T cells in inducing production 
of IFN-y and lymphocyte proliferation  (3-5).  In coopera- 
tion with other costimulatory molecules, IL-12 induces de- 
velopment of Thl cells during an immune response to an- 
tigen (6, 7) and is required for optimal proliferation and IFN-3, 
production by differentiated Thl cells (4, 8). The light chain 
(p35) and the heavy chain (p40) of IL-12 are encoded by two 
distinct  genes (9,  10); although only the covalently linked 
p70 heterodimer has known biological activity, the p40 heavy 
chain is always secreted in large excess over the heterodimer 
(2,  11). 
The expression or production of costimulatory molecules 
in monocytes/macrophages is regulated by several cytokines, 
which have either activating or deactivating effects on var- 
ious functions of these cells. IFN-3' and GM-CSF are among 
the stimulatory cytokines, enhancing IL-12 production and 
other functions of monocytes/macrophages (12, 13), whereas 
IL-10, IL-4, and TGF-/~ are usually considered as the most 
important deactivating factors (14). Through their effect on 
accessory cell functions,  this latter group of cytokines has 
an inhibitory effect on many responses of T and NK cells; 
however, they can also directly affect lymphocyte functions, 
for example, IL-IO inhibits production of IL-2 by T cells, II.-4 
inhibits the response to IL-2, and TGF-B inhibits the response 
to both IL-2 and IL-12 in T and NK cells (15-17, Scharton- 
Kerston, T., G. Trinchieri, and P. Scott, unpublished results). 
I1.-13 is a recently described cytokine that shares one chain 
(IL-2R3') of its receptor with the Ib4 and IL-2 receptors and 
mediates similar functions to those mediated by IL-4 on mono- 
cytes/macrophages  and B cells, but not on T  or NK cells 
(18-20). 
Unlike IL-10 and TGF-~, which appear to downmodulate 
many phagocytic cell functions,  the mode of action of IL-4 
and IL-13 is more complex. On monocytes/macrophages, IL-4 
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differentiation of these cells, whereas IFN-3, induces their 
differentiation. II.,4 or IL-13 treatment of monocytes induces 
the formation of long cytoplasmic protrusions that tightly 
adhere to substrates,  giving them a dendritic appearance (21). 
Addition of IL-4 to long-term monocyte cultures grown in 
the presence of GM-CSF blocks the differentiation to macro- 
phages and the expression of macrophage markers such as 
CD14 or Fc receptors, while inducing cells that resemble den- 
dritic/Langerhans cells with respect  to antigenic phenotype 
(e.g., expression of CD1) and potent APC functions (22, 23). 
Short-term treatment of monocytes with IL-4 or IL-13 en- 
hances the expression  of the surface antigens class II MHC, 
CD11b, CDllc, CD18, and CD23, but downregulates the ex- 
pression of CD16, CD32, and CD64 (14, 24-30).  Further- 
more, IL-4 and IL-13 inhibit production of IL-lot and -/3, IL-6, 
IL-8, IL-IO,  IL-12 p35  and p40,  GM-CSF, M-CSF, G-CSF, 
IFN-ol,  and TNF-ot,  but  enhance production of the IL-1 
receptor  antagonist (IL-1RA) 1 by monocytes (14, 30-35). 
However, in one study, IL-4 was shown to induce produc- 
tion of G-CSF and M-CSF from human monocytes (36). IL-4 
was also  shown to inhibit cytokine production, including 
TNF-ot, by mouse peritoneal macrophages, especially if these 
cells were pretreated with IL-4 before stimulation. However, 
IL-4 has  also  been reported to enhance or induce TNF-ct 
production in LPS-treated or Leishmania-infected  peritoneal 
macrophages (37, 38). These contrasting results may reflect 
the use of different cell populations and experimental condi- 
tions (39), but possibly also species differences, as suggested 
by the observation that pretreatment with IL-4 inhibits the 
stimulus-dependent respiratory burst in human monocytes 
but enhances it in murine macrophages (40). 
In this study, we show that pretreatment of PBMC with 
IL-4 or IL-13 for/>20 h enhances several fold their ability to 
produce IL-12 and TNF-ot in response to Staphylococcus aureus 
or LPS. This priming effect was reflected in a similar increase 
in stimulus-dependent accumulation of cytokine mRNA. 
Materials and Methods 
Cytokines and Reagents.  CHO cell-derived human rill2 was 
a gift from Dr. S. Wolf (Genetics Institute, Boston, MA); rlL-l~ 
(3.8  x  107 U/ml) was provided by the Division of Cancer Treat- 
ment  (National  Cancer Institute,  Bethesda, MD);  rlI~2 (107 
U/mg) by Dr. T. Taguchi (Osaka University, Osaka, Japan); CHO 
cell-derived rlL-10 (1.5  x  107  U/mg)  and  rlL-D  by Dr.  A. 
O'Garra (DNAX Research Institute, Palo Alto, CA), and rTNF-cr 
(5  x  107 U/mg) by Dr. H. M. Shepard (Genentech, South San 
Francisco, CA). The following reagents were purchased from com- 
mercial sources: rTGF-B1 (R&D Systems, Inc., Minneapolis,  MN); 
rlL4 (2  x  107 U/rag, Genzyme Corp., Cambridge, MA); PHA- 
M (Wellcome Diagnostics, Dartford, UK); fixed S. aureus Cowan 
strain 1 (Pansorbin; Calbiochem-Behring  Corp., La  Jolla, CA); LPS 
(from Esckerichia coli, serotype 0127:B8; Sigma  Chemical Co., St. 
1  Abbreviations used in this paper: GAPD, glyceraldehyde  phosphate de- 
hydrogenase;  IL-1RA,  IL-1  receptor  antagonist;  TPA, 12-O-tetradecanoyl- 
phorbol 13-acetate. 
Louis, MO); and 12-0-tetradecanoylphorbo113-acetate  (TPA; Sigma 
Chemical Co.) 
Antibodies and Cytokine Assays.  Neutralizing anti-IL-10 mAb 
19F1 and anti-IL-4 mAb 25D2 were kindly provided by Dr. A. 
O'Garra and anti-IL-1B  F18.609 and F18.206 were kindly provided 
by Dr. M. A. Cousin (Roussel-Uclaf, Romainville, France) (41). 
RIAs for human IFN-3' and human TNF-a were performed as 
described (42, 43) with mAbs B133.1/B133.5 and B154.9/B154.7, 
respectively. IL-12 p40 was measured in cell-free supernatants by 
ILIA as described (2) by use of the mAb pair Cll.79/C8.6. ILIA 
for IL-I~ was performed with mAbs F18 609/F18 206 (41). ELISA 
for  human  IL-10 was  purchased from  Biosource International 
(Camarillo, CA). 
quantitation  of Biologically Active 11_,12 Heterodimer by Antibody 
Capture Bioassay.  The biological activity of IL-12 was determined 
by use of the capture bioassay  previously  described (3). Briefly,  the 
anti-IL-12 p40 antibody Cll.5 (2) was absorbed (15/xg/ml,  100 
#l/well, in 0.1 M carbonate buffer, pH 9.5) for i>24 h at 4~  to 
bacteriological 96-well plates (Flow Laboratories, Inc., Rockville, 
MD). Plates were washed three times with PBS, and PBS/FCS 5% 
was added (200/zl,  1 h, 37~  After three washes, dilutions 
of rlIA2 standard or supernatant fluids to be tested were added 
(100/~l/well,  for 3 h,  at room temperature), plates were again 
washed (five times) and PHA blasts (5  x  10S/well) together with 
100 U/ml of rlL-2 were added to the plates. After an 18-h incuba- 
tion (37~  5% CO2), supernatants were collected and tested for 
IFN-3, production by ILIA. The assay  detects i>1 pg/ml of biolog- 
ically active IL-12, is specific  for Ib12, and, at least in the concen- 
tration range used in these experiments, is not affected  by the pres- 
ence of an excess of free p40 chains. 
CellLines and PBMC Preparation.  Peripheral  blood obtained  from 
healthy donors was anticoagulated  with heparin. PBMC were sepa- 
rated  on  Ficoll-Hypaque (Lymphoprep; Nyegaard Co.,  Oslo, 
Norway) density gradient. When monocytes were used, they were 
obtained after adherence of the PBMC to plastic flasks  by scraping 
the flasks  with a rubber policeman  after carefully  rinsing out nonad- 
herent cells with three washes with PBS. PHA blasts (>98% acti- 
vated  T  cells) were obtained after 3-d culture of PBL in the pres- 
ence of 1%  PHA-M (44, 45). The human EBV-transformed B 
lymphoblastoid cell line RPMI-8866 and the monocytic leukemia 
cell line THP-1 were grown in RPMI-1640 medium (Flow Labora- 
tories, Inc.,) supplemented with 10%  (20% for THP-1) heat- 
inactivated FCS (Irvine Scientific, Santa Ana, CA). All tissue cul- 
ture media and supplements were endotoxin flee. Cultures were 
performed in 96-well round-bottomed plates (Flow Laboratories, 
Inc.) with 106 cells/well. Cytokines to be tested were added at the 
onset of culture and kept in culture for 20 h before addition of 
the stimuli; supernatants  were harvested  after 18 h; IL-12  p40, TNF- 
or, IL-1B, or II.,10 release was determined by use of specific RIAs, 
and IL-12 p70, by antibody capture bioassay. In some experiments, 
neutralizing anti-IL-4 mAb (25D2), anti-IL-10 mAb (19F1), at a 
concentration of 10/zg/ml each, were added to PBMC at different 
times during the culture assays  before harvesting the supernatants 
for the specific RIAs. 
Northern Blot Hybridization.  Northern blots were performed as 
described (46). Briefly,  total RNA was extracted from induced and 
uninduced PBMC by the guanidine isothiocyanate  method. Equal 
amounts  of RNA  (15  /zg/lane) were fractionated  in  a  1% 
agarose-formaldehyde  gel. Gene expression was detected  by sequen- 
tial hybridization of nylon membranes (Schleicher  & Schuell, Inc., 
Keene, NH) with 32p-cDNA probes for IL-12 p40, TNF-o~, IL-1/~/, 
and glyceraldehyde  phosphate dehydrogenase  (GAPD). Filters  were 
exposed to film (X-Omat AR; Eastman Kodak Co., Rochester, 
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mington,  DE). 
RNase Protection  Assay.  The entire coding region of p35 IL12 
was amplified  by PCR and subcloned into the pCRT~II vector, ac- 
cording to the suggestions of the manufacturer (Invitrogen Co., 
San Diego, CA). The vector was linearized with appropriate re- 
striction  enzymes and  transcribed by use  of [32p]UTP (NEN 
DuPont Co., Wilmington, DE) and a riboprobe kit (Promega  Bio- 
tec, Madison,  WI) into a complementary  RNA (antisense)  riboprobe 
containing a region of 240 bp complementary  to the p35 IL-12  chain 
sequence. RNA samples (20/~g in 20/~1) were hybridized in solu- 
tion with an excess of riboprobes (8-10  x  104 cpm, sp act 109 
cpm//~g, 90~  for 5 min, 42~  for >10 h). RNase solution (200 
/~1) was added for 30 min at 37~  and the instructions of a ribo- 
nuclease protection assay  kit (model RPA II; Ambion Inc., Austin, 
TX) were followed. Protected fragments were fractionated on 5% 
polyacrylamide/urea sequencing gels and detected by autoradi- 
ography. 
Results 
Effect of Concomitant Treatment with IL-4, ILIO, and 71~F- 
El on LPS- and S. aureus-induced Production of  lL-12 and Other 
Cytokines by PBMC.  As previously reported (14, 30), stim- 
ulation of human PBMC with LPS or S. aureus in the pres- 
ence of Ib4 or IL-13 inhibited the production ofTNF-o~, IL-1B, 
and IL-10 (results  not shown). Production of the free IL-12 
p40 chain or the biologically active  IL-12 p70 heterodimer 
by LPS-stimulated PBMC was also inhibited by both IL-4 
and  II,-13 present  during  the  18-h  stimulation  (Table 1). 
Northern blotting analysis showed that LPS induced accumu- 
lation of transcripts for TNF-c~ (peak at 1 h), IL~  p40 (peak 
at 4-8 h), and IL-1B (peak at 1-8 h) in PBMC (Fig.  1). Like 
the observed effect on cytokine secretion, the presence of IL-4 
during stimulation profoundly inhibited expression  of both 
the IL-12 p40 and TNF-ol transcripts. These results extend 
the previous report that IL~ and IL-13 inhibit the accumulation 
of ILo12 transcripts induced by LPS in the presence of anti- 
IL-10 (30).  The accumulation of IL-1B transcripts was only 
minimally  decreased by Ib4, in contrast with the Ib4-mediated 
inhibition of IL-1B secretion (30 and Fig. 1). Unlike IL-4 in- 
hibition of LPS-induced IL-12 production, the inhibition by 
IL-4 or  IL-13 of IL-12 p40  or p70  production induced by 
S. aureus stimulation was often less consistent and, in most 
experiments, minimal or absent (Table 1). TGF-~/1 and IL-10 
effectively inhibited IL-12 production induced by either LPS 
or S. aureus (Table 1). 
PBMC Priming for IL-12 and TNF-e~ Production by Pretreat- 
ment with IL-4 or IL-13.  Unlike the inhibitory effects exerted 
by IL-4 and IL-13 when present during stimulation, pretreat- 
merit of PBMC for 20 h with IL-4 or IL-13 induced a three- 
to fourfold enhancement in their ability to produce IL-12 p40 
and p70 in response  to either LPS or S. aureus, and an ap- 
proximately twofold increase in the production of TNF-c~, 
whereas IL-I~ and IL-10 production in response  to LPS was 
inhibited (Tables 1 and 2). The inhibitory effect of TGF-B1 
or IL-10 on IL-12 p40 and p70 production induced by either 
S. aureus or LPS was observed when PBMC were either stimu- 
lated in the presence of TGF-~I or IL-10 or were pretreated 
for 20  h  with the two cytokines (Table  1). 
Neutralizing anti-IL-4 antibodies suppressed the ability of 
IL-4 to prime PBMC for IL-12 p40 production in response 
to S. aureus (Fig. 2), indicating that this priming effect was 
mediated by IL-4 and not by contaminants in the prepara- 
tion. Similar results were obtained with enriched monocyte 
preparations  (adherent PBMC) instead of total PBMC (Table 
3 and results not shown). Pretreatment of the macrophage- 
like cell line THP-1 with IL-4 also increased the production 
of IL-12 p40 in response  to LPS and, to a lesser extent, S. 
aureus; however, ILo4  neither enhanced nor inhibited the con- 
stitutive or TPA-induced production of II,-12 p40 from the 
EBV-transformed B  lymphoblastoid cell  line  RPMI-8866 
(Table 3). 
Northern blot analysis (Fig. 3) showed that, like the effect 
of IL-4 on cytokine secretion, IL-4  pretreatment enhanced sever- 
alfold the accumulation of IL-12 p40 and TNF-c~ mRNA in- 
duced by either LPS or S. aureus. Unlike IL-4, pretreatment 
with TGF-~I inhibited accumulation of the transcripts for 
the two cytokines. Accumulation of the IL-12 p35 mRNA, 
much less abundant than p40 mRNA, was analyzed by the 
RNase protection method. Ib12 p35 transcripts were induced 
by LPS or S. aureus with a kinetics similar  to that of IL-12 
p40 mR.NA (Fig.  3 and not shown), and this induced ac- 
cumulation was also enhanced severalfold by pretreatment 
of the PBMC with IL-4. 
Inhibition of ILIO Production Does Not Play a Major Role 
in the Priming Effect of  lL-4 and IL13 on IL12 Production.  Be- 
cause monocytes produce ILol0, a potent inhibitor of IL-12 
production (3) (Fig. 4),  and because IL-10 production is in- 
hibited by IL-4 (30) (Table 2), we tested the possibility that 
the priming effect of IL-4 and IL-13 was mediated by their 
inhibition of IL-10 production. However, in the present ex- 
perimental conditions, ILo4 and ILo13 induced only a partial 
inhibition of LPS-induced IL-10  production and had no demon- 
strable effect on S. aureus-induced production (Table 2). Fur- 
Figure 1.  Effect  of  rlL-4 on the LPS-induced  accumulation  of IL-12  p40, 
TNF-~x, and IL-1/~  mRNA in human  PBMC. Total  RNA was extracted 
from PBMC incubated  for the indicated  times  in tissue culture  medium 
or in the presence of LPS (1/~g/ml)  with or without 10 ng/ml of human 
rib4. Cells stimulated  in the presence  oflb4 were  pretreated  for 4 h with 
the same concentration  of Ib4. The RNA (15/~g/lane)  was then hybrid- 
ized in a Northern blot with 32p-labeled IL-12 p40, TNF-cx, Ibl~, or 
GAPD cDNA probes. 
539  D'Andrea  et al. Table  1.  Effect of Simuhaneous  Addition  or Pretreatment with IL-4 and IL-I3  on  the  LPS- and S.  aureus-induced Production  of lL-12 
by PBMC 
Time of 
preincubation  Cytokine  Stimulus  IL-12 p40  IL-12  p70 
h*  pg/ml 
(n  =  14)  (n  =  3) 
None  Medium  161  _+  79  <8 
0  IL-13  Medium  152  _+  68  <8 
0  IL-4  Medium  92  _+  38  16  _+  10 
None  S.  aureus  15,857  _+  3,472  239  _+  205 
20  IL-13  S.  aureus  61,214  _+  12,828  893  _+  370 
0  IL-13  S.  aureus  18,515  _+  4,410  366  _+  320 
20  IL-4  S.  aureus  48,031  _+  7,487  869  _+  434 
0  IL-4  S.  aureus  13,402  _+  4,165  60  _+  48 
None  LPS  1,720  _+  599  157  _+  141 
20  IL-13  LPS  5,584  _+  996  725  +  266 
0  IL-13  LPS  814  _+  237  27  _+  20 
20  IL-4  LPS  3,832  _+  764  888  _+  446 
0  IL-4  LPS  296  _+  91  89  +  87 
(n  =  4)  (n  =  3) 
None  Medium  79  __  25  <8 
0  TGF-/3  Medium  120  _+  64  <8 
0  IL-10  Medium  25  _+  13  <8 
None  S.  aureus  10,340  _+  2,222  239  _+  204 
20  TGF-/~/  S.  aureus  1,213  _+  435  18  _+  15 
0  TGF-/~/  S.  aureus  4,690 _+ 1,256  89  _+ 52 
20  IL-10  S.  aureus  1,719 _+ 456  27  _+ 17 
0  IL-10  S.  aureus  398  _+ 115  <8 
None  LPS  387  _+ 174  157  __ 140 
20  TGF-/3  LPS  324  _+ 97  <8 
0  TGF-3  LPS  105  _+ 5  <8 
20  IL-10  LPS  180 _+ 78  8 +_ 6 
0  II.-10  LPS  37 _+ 10  17 _+ 12 
* IL-4 (10 ng/ml) or IL-13 (10 ng/ml) was added to PBMC cultures 20 h before or at the time of stimulation with S. aureus (1:10,000 wt/vol) or 
with LPS (1/xg/ml). Cell-free supernatant fluids were collected after 18 h of stimulation; IL-12  p40 was determined by RIA and I1.-12 p70 by antibody- 
capture bioassay. Results are mean  _+  SE of n experiments. 
thermore,  anti-IL-10 antibodies  enhanced production of IL- 
12 p40 from both untreated and IL-4- or IL-13-primed PBMC 
(Fig. 4). Thus, although endogenous IL-10 has an inhibitory 
effect on IL-12 p40 production,  inhibition  of IL-10 produc- 
tion is unlikely to be an important mechanism in the IL-4/IL- 
13-mediated priming in light of the at least  additive effect 
of IL-4/IL-13 priming with anti-IL-10. However, addition of 
exogenous IL-10 almost completely inhibited IL-121040 produc- 
tion by either untreated or IL-4/IL-13-primed PBMC (Fig. 4). 
Kinetics and Dose Dependence  of the Priming  Effect of lL4 
and IL13  on 11,12 p40 Production.  The maximum priming 
effect (20-h pretreatment) of both IL-4 and Ib13 for produc- 
tion of IL-12 p40 from human PBMC was observed at con- 
centrations  of 1-10 ng/ml.  No significant increase in IL-12 
p40 production was observed with any doses of ILo4 or ILo13 
between 1 pg/ml and 10 ng/ml added during the 18-h stim- 
ulation, and an inhibitory effect was observed with the highest 
doses of IL-4 and IL-13 present during the 18-h-stimulation 
with LPS, but not consistently with S.  aureus (Fig.  5).  An 
optimal  priming  effect  was  observed  when  PBMC  were 
pretreated  with  IL-4 or IL-13 for at  least  20-24 h  (Fig.  5). 
In longer-term cultures,  the IL-4-mediated enhancement of 
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TNF-cr  IL-1B  IL-10 
Cytokine*  Stimulus  (n  =  16)  (n  =  6)  (n  =  4) 
l,g/ml 
None  Medium  13  _+  4  1,322  _+  1,321  25  _+  3 
IL-4  Medium  27  _+  7  54  _+  54  23  _+  4 
IL-13  Medium  19  +  6  181  +  126  22  +_  2 
None  S.  aureus  1,679  _+  260  19,105  __.  3,601  103  _+  73 
IL-4  S.  aureus  2,628  _+  314  12,935  _+  2,855  177  +_  77 
IL-13  S.  aureus  2,636  _+  31  21,834  _+  3,104  129  _+  67 
None  LPS  236  _+  42  14,108  _+  9,307  80  _+  30 
IL-4  LPS  512  _+  89  5,682  _+  3,805  41  _+  11 
IL-13  LPS  604  _+  99  7,130  +_  4,473  43  _+  14 
*  IL-4 (10/~g/ml) or IL-13 (10 #g/ml) was added to PBMC cultures. After a 20-h incubation, cultures were stimulated with S. aureus (1:10,000 
wt/vol) or LPS (1/xg/ml). Cell-free supernatant fluid was collected after an 18-h stimulation, and TNF-~x, IL-I~, and IL-10 were quantitated by 
immunoassays. ILesults are mean  _+  SE of n experiments. 
monocyte ability to produce IL-12 and TNF-ot was observed 
in up  to  3  d  of culture  (not  shown). 
Discussion 
The data presented here show  that  treatment  of PBMC 
with  IL-4 or IL-13  for  />20  h  primes them  for production 
of IL12 and TNF-cz in response to S. aureus and LPS, whereas 
their ability to produce IL-1B or IL-10 in response to LPS 
is impaired. These data contrast with the well-described ability 
of IL4 and IL-13, at least when added at the beginning or 
a few hours before stimulation of monocytes/macrophages. 
to inhibit production of a large number of cytokines, with 
the sole exception of IL-1RA (14, 30). However, the ability 
of IL4 in some experimental conditions to act as costimulus 
for production of G-CSF and M-CSF from human mono- 
cytes (36) and TNF-ot from mouse peritoneal macrophages 
(37,  38)  has been reported. Thus,  the regulation of activa- 
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Figure 2.  Specificity  of IL-4  in the enhancement of Ib12 p40 production 
by PBMC. Human PBMC were precultured in medium alone or medium 
supplemented  with rll_,4  (10 ng/ml) and/or neutralizing  anti-IL-4  (10/~g/ml) 
for 20 h (solid bars) before adding S. aureus (1:10,000 wt/vol); alternatively, 
rlL-4 and/or anti-IL-4 were added at the same time as the S. aureus (open 
bars). After an 18-h incubation in the presence orS. aureus, cell-free  super- 
natant fluids were collected and tested for the presence of ID12 p40 by 
ILIA. Results are mean  +  SE (n  =  11). 
Table  3.  Effect  of lL-4 on IL-12 p40 Production by Cell Lines 
IL-4  IL-4 
Cells*  Stimulus  Medium  (0 h)  (- 20 h) 
Monocytes 
THP-1 
RPMI-8866 
IL- I 2 .p40 (pg  /ml) 
--  52  64  152 
S.  aureus  2,074  74  20,409 
LPS  562  242  2,307 
-  51  27  57 
S.  aureus  104  85  288 
LPS  2,215  1,987  6,734 
-  3,941  3,783  4,534 
S.  aureus  3,986  3,983  4,132 
TPA  7,953  8,125  7,967 
* The macrophagic cell line THP-1  and the EBV-transformed B lym- 
phoblastoid cell line RPMI-8866 were stimulated for 18 h with S. aureus 
(1:10,000 wt/vol), LPS (1 #g/ml), or TPA (1.6  x  10 -7 M) in medi- 
um only, in the presence (0 h) of IL-4 (10 ng/ml), or after a 20-h pretreat- 
ment with IL-4. After an 18-h stimulation, cell-free supernatant fluids 
were collected and IL-12 p40 was measured by ILIA. A representative 
experiment is shown for each cell line and for a preparation of adherent 
PBMC (>95%  monocytes). 
541  D'Andrea et al. Figure  3.  Effect of rib4 and rTGF-•  on the induction of Ib12 p35, 
Ib12 p40,  and TNF-a mRNA accumulation  in human PBMC treated 
with LPS (1/zg/ml) or S. aureus (1:10,000 wt/vol). Cells were preincubated 
for 20 h at 37~  in medium alone or medium supplemented with 10 ng/ml 
rib4 or rTGF-~ before LPS or S. aureus stimulation (18 h). For IL-12 1>40 
and TNF-a, 15/~g total RNA was loaded per lane. Filters were sequen- 
tially hybridized  with 32p-labeled Ib12 p40,  TNF-a, and GAPE) cDNA 
probes.  The bottom panel  shows the autoradiography  of the Northern 
blot of one of two experiments  with similar results. For II.-12 p35, total 
RNA (20/zg) in solution was hybridized  with 32p-riboprobe transcribed 
from Ib12 p35 cDNA, and mR.NA accumulation  was analyzed by RNase 
protection. Both Northern blot hybridization  and RNase protection were 
quantitated  by use of a phosphoimager.  Results in the bar plots are given 
as percentage of maximum accumulation  after normalizing to the GAPD 
values. Open and  solid bars indicate  the results  of two experiments. 
tion and cytokine production mediated by IL-4 or ILo13 in 
monocytes/macrophages  appears to be much more complex 
than that observed with IL-10 or TGF-B, cytokines that usu- 
ally function as deactivating  agents for monocytes/macro- 
phages. In addition,  the ability of IL-4 and IL-13 to reduce 
production of I1.-12 and other cytokines when present during 
stimulation of  PBMC appears to depend on the stimulus used. 
In contrast to IL-10 and TGF-/~I, which consistently inhibited 
cytokine production induced by either LPS or S. aureus, IL-4 
and IL-13 often failed to inhibit cytokine production in re- 
sponse to S.  aureus and were always less potent in inhibiting 
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Figure 4.  Role ofi1r  in Ib121040 production by PBMC after pretreat- 
ment with rlL-4 or rlL-13. Human PBMC were preincubated  for 20 h 
in medium alone (open bars) or in medium supplemented  with 10 ng/ml 
of rlL-4 (solid  bars)  or rib13  (striped  bars)  in the presence or absence of 
either rlL-10 (50 U/ml) or anti-IL-10 mAb (ascites 1:100), followed by ad- 
dition ofS. aureus (1:10,000 wt/vol) or LPS (1/~g/ml). IL-12  p40 produc- 
tion was determined  after an 18-h incubation by use of an RIA. Results 
are presented  as mean  +  SE (n  =  3). 
S. aureus-induced  cytokine  production when compared with 
their inhibition of LPS-induced cytokine production. 
The inhibition of IL-12 and TNF-a production and, par- 
tially, of IL-1/~ production by IL-4 is reflected by a decrease 
in accumulation  of their mP,  NA in LPS-stimulated  cells. 
Previous studies (31) have indicated that this effect of IL-4 
may be mediated by both transcriptional  and posttranscrip- 
tional mechanisms. Unlike the inhibitory effect of IL-4 and 
IL-13 when present  together with  the cytokine-inducing 
stimulus,  preincubation  of PBMC with II.-4 and II:13 for 
>120 h primed the cells for production of IL-12 and TNF-c~ 
in response to both S.  aureus  and LPS, resulting  in a three- 
to fourfold increase of both mRNA accumulation and pro- 
tein secretion. In the absence of a cytokine-inducing stimulus 
such as S.  aureus or LPS, IL-4 did not have a direct stimula- 
tory effect on the mRNA accumulation or production of ei- 
ther IL-12 or TNF-ot.  The priming effect of IL-4 and IL-13 
was demonstrable on the induction of  both the p35 and p40 
genes. However, the ratio between the transcripts  was not 
changed by priming, and, like unprimed cells, the IL-4- or 
IL-13-primed PBMC secreted the IL-12 p40 chain in large 
excess over the biologically active  IL-12 p70 heterodimer. These 
effects of  II.-4 and IL-13 contrast with those of  IFN-% which 
directly stimulate  expression of the p35  gene and induce 
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Effect oflb4 and IL-13  on IL-12  p40 production. (A) Human 
PBMC were preincubated (for 20 h at 37~  in the absence (O-O) or 
presence (O-O) of increasing concentrations of human rlL-4 or rlL-13 fol- 
lowed by the addition of LPS (1 #g/ml) or S. aureus (1:10,000 wt/vol). 
After an 18-h incubation at 37~  cell-free supernatant fluids were col- 
lected and tested for the presence of II-12 p40. Results are mean -+ SE 
(n = 4). (B) Human PBMC were preincubated  with human riD4 or riL- 
l3 (10 ng/ml) for the time periods  indicated, after which  S. aureus (1:10,000) 
was added and the cells were cultured for an additional 18 h. Supernatant 
fluids were  collected  and tested  for the presence  of II:12 i040. Results (A-A) 
are mean _+ SE (n = 3). Dashed lines in all panels represent the amount 
of IL-12 produced in the absence of treatment with either II-4 or II.-13. 
priming for IL-12 p70 production more effectively than for 
IL-12 p40 production  in both monocytes (13)  and neutro- 
phils  (46a). 
The ability of IL-4 to prime PBMC for cytokine produc- 
tion was not due to contaminants present in the preparation, 
because identical results were obtained with recombinant IL-4 
from three different sources (not shown), and the effect was 
completely blocked by neutralizing anti-IL-4 antibodies. The 
nearly identical  results  obtained with  IL-4 and  IL-13, two 
cytokines that  share  many biological actions,  confirms  the 
specificity of the priming  effect.  Because IL-4 and IL-13 in- 
hibit phagocytic cell production of IL-10, a powerful inhib- 
itor of IL-12 and TNF-o~ production, it was possible that the 
priming effect of IL-4 and IL-13 on the production of these 
two cytokines was due to inhibition of IL-IO production. How- 
ever, our data do not support this hypothesis because (a) IL-4 
and IL-13 prime PBMC for production of IL-12 and TNF-ot 
in response to S. aureus, whereas they have only limited ability 
to inhibit IL-IO production in response to this stimulus; and 
(b) neutralizing anti-Ibl0 antibodies enhance production of 
1I.-12 in response to either LPS and S.  aureus by abolishing 
the inhibitory effect of endogenous IL-10, and this effect is 
synergistic with IL-4 or IL-13 priming,  indicating  that  the 
ability of IL-4- or IL-13-primed PBMC to produce IL-12 is 
still inhibited by endogenous IL-10. Thus, although the inhi- 
bition of IL-10 may play a minor role in the mechanisms of 
IL-4 or Ib13 priming,  especially in the case of LPS stimula- 
tion, the major mechanism of the priming appears to be in- 
dependent  of inhibition  of IL-10 production. 
The ability of IL-4 and IL-13 to prime PBMC for 1I.-12 
production is particularly surprising because IL-12 and IL-4 
are known to play an antagonistic role in inducing develop- 
ment of Thl  and Th2 immune response, respectively (47). 
The equilibrium between IL-12 and IL-4 early during an im- 
mune response most likely determines whether the response 
is Thl or Th2 (48). However, it is likely that several modula- 
tory mechanisms  and both positive and negative feedback 
mechanisms intervene in the fine regulation of the Thl/Th2 
dichotomy. Ib4 acts not only by downmodulating costimula- 
tory signals expressed or secreted by accessory cells, but also 
by preventing the responsiveness of T cells to IL-2 (49).  The 
priming effect of IL-4 and IL-13 on IL-12 production by PBMC 
is almost completely suppressed by IL-IO,  another cytokine 
prevalently produced by Th2 cells, suggesting that the priming 
effect of IL-4 on II.-12 production is not effective when a Th2 
response predominates. Even in the presence of high concen- 
trations  of Ib12 during  an immune  response,  factors such 
as TGF-3 may suppress Thl cell differentiation in response 
to 11-12 and favor Th2 cell differentiation (Scharton-Kersten, 
T., L. C. C. Afonso, M. Wysocka, G. Trinchieri,  and P. Scott, 
manuscript submitted for publication). Other exceptions to 
the rule that  II.-4 and IL-12 favor Th2 and Thl  differentia- 
tion, respectively, include the findings that  IL-12 enhanced 
IL-4 production by IL-4-primed  human cord blood CD4 § 
cells (50),  and that  IL-12 in vivo induced IL-10 production 
in the mouse (51). 
The ability of IL-4 and IL-13 to prime monocytes for IL-12 
and TNF-ol production is likely reflected in enhanced acces- 
sory cell activity of these cells. We observed that  IL-4- and 
IL-13-primed PBMC have an enhanced ability to act as APC 
for antigen-induced  IFN-'y production by most human tetanus 
toxoid-specific  CD4 +  clones  (results  not  shown).  IL-12 
production  from APC plays  an important  role in antigen- 
induced IFN-y production and, to some extent, in prolifera- 
tion of CD4 § clones (4). Thus, it is likely that the enhanced 
production of IL-12 is important  for the enhanced APC ac- 
tivity of IL-4- and IL-13-primed cells, although other effects 
of IL-4, in particular the enhanced expression of MHC class 
II and other costimulatory factors such as TNF-c~, may play 
a role (52, 53). The exact mechanism of the enhanced APC 
activity of IL-4- and IL-13-primed PBMC remains to be charac- 
terized. We have also observed that IL-4 and 11-13 treatment 
543  D'Andrea  et al. of monocytes enhances their ability to mediate TNF-ot-de- 
pendent cytotoxicity of the WEHI-164 cell line (results not 
shown), contrasting with the ability of IL-4 to inhibit antibody- 
dependent cell-mediated cytotoxicity, due to inhibition of ex- 
pression of Fc receptor on monocytes/macrophages (14, 37). 
Not only does short-term treatment of PBMC with IL-4 or 
IL-13 enhances their APC  function and ability to support 
antigen-dependent IFN-'y production, but long-term cultures 
of monocytes in the presence of GM-CSF and Ib4 give rise 
to cells with dendritic-like  phenotype, which are very powerful 
APC  (22,  23)  and  extremely effective producers of IL-12 
(Kubin, M., and G. Trinchieri, unpublished results). These 
data suggest that IL-4 and IL-13, primary products of Th2 
cells, might play a role in the differentiation and activation 
of APC, which, in the absence of other regulatory mecha- 
nisms,  produce large amounts of IL-12 and may favor Thl 
cell development. The role of this activity of IL-4 or IL-13 
in the complex regulatory interactions of the immune response 
remains to be clarified. 
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